A comparison of the predictive accuracy of three screening models for pulmonary arterial hypertension in systemic sclerosis

Arthritis Research and Therapy

Volumn 17, Issue 1, 2015, Pages

  Hao, Yanjie ^a,b   Thakkar, Vivek ^a,c,d   Stevens, Wendy ^a   Morrisroe, Kathleen ^a   Prior, David ^a   Rabusa, Candice ^a   Youssef, Peter ^e   Gabbay, Eli ^f   Roddy, Janet ^g   Walker, Jennifer ^h   Zochling, Jane ⁱ   Sahhar, Joanne ^j   Nash, Peter ^k   Lester, Susan ^l   Rischmueller, Maureen ^l,n   Proudman, Susanna M ^m,n   Nikpour, Mandana ^a,o  

^a ST VINCENT S HOSPITAL   (Australia)

^b PEKING UNIVERSITY FIRST HOSPITAL   (China)

^c LIVERPOOL HOSPITAL   (Australia)

^d UNIVERSITY OF WESTERN SYDNEY   (Australia)

^e ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^f UNIVERSITY OF NOTRE DAME   (Australia)

^g ROYAL PERTH HOSPITAL   (Australia)

^h FLINDERS MEDICAL CENTRE   (Australia)

ⁱ The Menzies Institute Tasmania Department of Rheumatology   (Australia)

^j MONASH MEDICAL CENTRE   (Australia)

^k UNIVERSITY OF QUEENSLAND   (Australia)

^l QUEEN ELIZABETH HOSPITAL   (Australia)

^m ROYAL ADELAIDE HOSPITAL   (Australia)

ⁿ UNIVERSITY OF ADELAIDE   (Australia)

^o UNIVERSITY OF MELBOURNE   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ALGORITHM; ARTICLE; CONTINGENCY TABLE; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HEART CATHETERIZATION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PREDICTIVE VALUE; PREVALENCE; PULMONARY HYPERTENSION; SENSITIVITY AND SPECIFICITY; SYSTEMIC SCLEROSIS; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; HYPERTENSION, PULMONARY; MASS SCREENING; MIDDLE AGED; MULTICENTER STUDY; PROCEDURES; SCLERODERMA, SYSTEMIC; STANDARDS;

AGED; ALGORITHMS; COHORT STUDIES; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MASS SCREENING; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; SCLERODERMA, SYSTEMIC;

EID: 84924325369     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-015-0517-5     Document Type: Article

References (27)

1. Lefèvre G, Dauchet L, Hachulla E, Montani D, Sobanski V, Lambert M, et al. Survival and prognostic factors in systemic sclerosis-associated pulmonary hypertension: a systematic review and meta-analysis. Arthritis Rheum. 2013;65:2412-23.
2. Humbert M, Yaici A, de Groote P, Montani D, Sitbon O, Launay D, et al. Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. Arthritis Rheum. 2011;63:3522-30.
3. Galiè N, Rubin LJ, Hoeper MM, Jansa P, Al-Hiti H, Meyer G, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet. 2008;371:2093-100.
4. Chung L, Domsic RT, Lingala B, Alkassab F, Bolster M, Csuka ME, et al. Survival and predictors of mortality in systemic sclerosis associated pulmonary arterial hypertension: Outcomes from the PHAROS registry. Arthritis Care Res (Hoboken). 2014;66:489-95.
5. Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009;30:2493-537.
6. Kowal-Bielecka O, Avouac J, Pittrow D, Huscher D, Behrens F, Denton CP, et al. Echocardiography as an outcome measure in scleroderma-related pulmonary arterial hypertension: a systematic literature analysis by the EPOSS Group. J Rheumatol. 2009;37:105-15.
7. Mathai SC, Sibley CT, Forfia PR, Mudd JO, Fisher MR, Tedford RJ, et al. Tricuspid annular plane systolic excursion is a robust outcome measure in systemic sclerosis-associated pulmonary arterial hypertension. J Rheumatol. 2011;38:2410-8.
8. Meune C, Avouac J, Airo' P, Beretta L, Dieudé P, Wahbi K, et al. Prediction of pulmonary hypertension related to systemic sclerosis by an index based on simple clinical observations. Arthritis Rheum. 2011;63:2790-6.
9. Schreiber BE, Valerio CJ, Keir GJ, Handler C, Wells AU, Denton CP, et al. Improving the detection of pulmonary hypertension in systemic sclerosis using pulmonary function tests. Arthritis Rheum. 2011;63:3531-9.
10. Mukerjee D, St George D, Knight C, Davar J, Wells AU, Du Bois RM, et al. Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology (Oxford). 2004;43:461-6.
11. Thakkar V, Stevens MW, Prior D, Moore OA, Byron J, Liew D, et al. N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control study. Arthritis Res Ther. 2012;14:R143-53.
12. Allanore Y, Borderie D, Avouac J, Zerkak D, Meune C, Hachulla E, et al. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Arthritis Rheum. 2008;58:284-91.
13. Thakkar V, Stevens W, Prior D, Youssef P, Liew D, Gabbay E, et al. The inclusion of N-terminal pro-brain natriuretic peptide in a sensitive screening strategy for systemic sclerosis-related pulmonary arterial hypertension: a cohort study. Arthritis Res Ther. 2013;15:R193.
14. Coghlan JG, Denton PC, Grünig E, Bonderman D, Distler O, Khanna D, et al. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis. 2013;00:1-10.
15. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American rheumatism association diagnostic and therapeutic criteria committee. Arthritis Rheum. 1980. 23:581-590.
16. LeRoy EC, Medsger Jr TA. Criteria for the classification of early systemic sclerosis. J Rheumatol. 2001;28:1573-6.
17. PAH risk calculator [http://detect-pah.com]
18. Macintyre N, Crapo RO, Viegi G, Johnson DC, van der Grinten CP, Brusasco V, et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J. 2005;26:720-35.
19. Avouac J, Airo P, Meune C, Beretta L, Dieude P, Caramaschi P, et al. Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and meta-analysis of 5 studies. J Rheumatol. 2010;37:2290-8.
20. Shah AA, Wigley FM, Hummers LK. Telangiectases in scleroderma: a potential clinical marker of pulmonary arterial hypertension. J Rheumatol. 2010;37:98-104.
21. Launay D, Humbert M, Berezne A, Cottin V, Allanore Y, Couderc LJ, et al. Clinical characteristics and survival in systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease. Chest. 2011;140:1016-24.
22. Kampolis C, Plastiras S, Vlachoyiannopoulos P, Moyssakis I, Tzelepis G. The presence of anti-centromere antibodies may predict progression of estimated pulmonary arterial systolic pressure in systemic sclerosis. Scand J Rheumatol. 2008;37:278-83.
23. Dimitroulas T, Giannakoulas G, Dimitroula H, Sfetsios T, Parcharidou D, Karvounis H, et al. Significance of serum uric acid in pulmonary hypertension due to systemic sclerosis: a pilot study. Rheumatol Int. 2011;31:263-7.
24. Jiang X, Han ZY, Wang Y, Xu XQ, Ma CR, Wu Y, et al. Hemodynamic variables and clinical features correlated with serum uric acid in patients with pulmonary arterial hypertension. Chin Med J (Engl). 2008;121:2497-503.
25. Fox BD, Shimony A, Langleben D, Hirsch A, Rudski L, Schlesinger R, et al. High prevalence of occult left heart disease in scleroderma-pulmonary hypertension. Eur Respir J. 2013;42:1083-91.
26. Hinchcliff M, Fischer A, Schiopu E, Steen VD, PHAROS Investigators. Pulmonary hypertension assessment and recognition of outcomes in scleroderma (PHAROS): baseline characteristics and description of study population. J Rheumatol. 2011;38:2172-9.
27. Condliffe R, Kiely DG, Peacock AJ, Corris PA, Gibbs JS, Vrapi F, et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med. 2008;179:151-7.